

$E_{280}^{1\%} = 9.1$ [20] and M_r 725 000 [21]. The concentration of TLCK-trypsin was determined using $E_{280}^{1\%} = 15.4$ and M_r 24 000 [22]. The concentration of insulin was determined by amino acid analysis. [^{14}C]Methylamine was from New England Nuclear (Boston MA) (48 Ci/mol) or the Radiochemical Centre (Amersham) (53 Ci/mol). [1,4- ^{14}C]Putrescine (122 Ci/mol) was from Amersham. Methylamine \cdot HCl and putrescine \cdot 2 HCl was from Sigma (St Louis MO). A stock solution of $\alpha_2\text{M}$ (15.0 μM) in 0.05 M Na-phosphate, 0.1 M NaCl (pH 8.0) was used. A stock solution of trypsin was in 1 mM HCl (CHOM-purified trypsin, active site titre 183 μM). Solutions of TLCK-trypsin (133 μM) and TLCK- ^{125}I -trypsin (133 μM) were in 0.1 M Na-phosphate (pH 8.0) (buffer A). Solutions of 0.05–1.0 M radio-labelled methylamine and putrescine were in buffer A. The extent of incorporation of ^{14}C -labelled methylamine and putrescine into $\alpha_2\text{M}$ was measured by precipitating $\alpha_2\text{M}$ with 10% trichloroacetic acid on discs of Whatman 3 MM filter paper and removing free amine with 5% trichloroacetic acid and ethanol/acetone (1:1, v/v) [2]. Since the denaturation of $\alpha_2\text{M}$ with trichloroacetic acid also results in complete cleavage of any remaining unreacted thiol ester we found it necessary to include NH_3 as a 'competing' nucleophile in this assay [2].

3. Results and discussion

At <1 mol trypsin/mol $\alpha_2\text{M}$, 4 mol SH appear/mol trypsin added. Maximally 4 mol SH appear at >2 mol trypsin/mol $\alpha_2\text{M}$ [2].

To investigate if activation of the thiol ester of $\alpha_2\text{M}$ by proteinases generate an 'acyl transfer' potential as postulated [2,5,6] $\alpha_2\text{M}$ was activated by incubating for 1 min with increasing concentrations of trypsin in the presence of [^{14}C]methylamine or [^{14}C]putrescine. Fig.1 shows that the extent of covalent incorporation of these two amines into $\alpha_2\text{M}$ parallels the trypsin-induced appearance of SH-groups [2]. Thus, the results show that $\alpha_2\text{M}$ when activated by proteinases can react rapidly to covalently incorporate primary amines. Despite the inclusion of NH_3 in the assay mixture the values of methylamine and of putrescine incorporated into $\alpha_2\text{M}$ in the absence of trypsin were found to be 0.40 and 0.55 mol/mol $\alpha_2\text{M}$, respectively. The incorporation of these amines at 25 mM in the presence of 1 mol trypsin/mol $\alpha_2\text{M}$ was 2.4–2.5 mol/mol $\alpha_2\text{M}$; and 2.7–2.9 mol/mol $\alpha_2\text{M}$




Fig.1. Incorporation of CH_3NH_2 and putrescine into $\alpha_2\text{M}$ at different trypsin concentrations. For each point 10 μl $\alpha_2\text{M}$ (15.0 μM) was mixed with 5 μl CHOM-purified trypsin (diluted from 120 μM) and 10 μl CH_3NH_2 or putrescine (62.5 mM). After incubation for 60 s at room temperature 25 μl 1 M NH_4HCO_3 was added. [$\alpha_2\text{M}$] = 6.0 μM ; [trypsin] = 1.5–24 μM ; [CH_3NH_2] or [putrescine] = 25 mM. A 40 μl aliquot was spotted on a filter disc and the $\alpha_2\text{M}$ precipitated with 10% trichloroacetic acid as in section 2. CH_3NH_2 , (●); putrescine (■).

at 4 mol trypsin/mol $\alpha_2\text{M}$. The amount of CH_3NH_2 bound at 100 mM CH_3NH_2 was ~ 3.0 mol/mol $\alpha_2\text{M}$ at 2 mol trypsin/mol $\alpha_2\text{M}$. At 0.44 mM CH_3NH_2 0.3 mol/mol $\alpha_2\text{M}$ was bound, showing that covalent binding may occur even at this, much lower, concentration of the nucleophile. Thus, the proteinase-induced activation of the $\alpha_2\text{M}$ -thiol esters apparently makes the reactive Glx-residues, which are normally available only to slow covalent incorporation of small primary amines, e.g., CH_3NH_2 [1–3], accessible to fast covalent incorporation not only of CH_3NH_2 but also of the larger putrescine. This ability for fast covalent incorporation of amines turned out to be a fleeting activity of the trypsin-activated $\alpha_2\text{M}$ which decreases rapidly as shown in fig.2, where $\alpha_2\text{M}$ was first activated with trypsin (2 mol/mol $\alpha_2\text{M}$) and then, after a variable delay of 5–120 s, incubated with CH_3NH_2 for 60 s. However, it is also evident from fig.2 that even after 120 s as much as 0.5 mol CH_3NH_2 /mol $\alpha_2\text{M}$ could still be bound covalently.

In separate experiments we found that at 2 mol trypsin bound/mol $\alpha_2\text{M}$ (in the absence of CH_3NH_2)




Fig. 2. Incorporation of CH_3NH_2 into $\alpha_2\text{M}$ which had been activated with trypsin before adding the CH_3NH_2 . To $20\ \mu\text{l}$ $\alpha_2\text{M}$ ($15.0\ \mu\text{M}$) $10\ \mu\text{l}$ CHOM-purified trypsin ($60\ \mu\text{M}$) was added, followed by addition of $20\ \mu\text{l}$ $^{14}\text{CH}_3\text{NH}_2$ ($62.5\ \text{mM}$) at a certain time interval after trypsin addition. $[\text{trypsin}] = 12.0\ \mu\text{M}$; $[\alpha_2\text{M}] = 6.0\ \mu\text{M}$; $[\text{CH}_3\text{NH}_2] = 25\ \text{mM}$. The mixtures were then incubated for 60 s after which $40\ \mu\text{l}$ $1\ \text{M}\ \text{NH}_4\text{HCO}_3$ was added. Then an $80\ \mu\text{l}$ aliquot was spotted on a filter disc and the $\alpha_2\text{M}$ precipitated with 10% trichloroacetic acid as in section 2.

~ 1.3 mol trypsin was bound 'covalently' in the sense that it was not separated from $\alpha_2\text{M}$ when the DTT-treated, carboxymethylated complex was gel-filtered in $6\ \text{M}$ guanidine-HCl at pH 8.0 [18]. When CH_3NH_2 was present during trypsin-induced activation of $\alpha_2\text{M}$, the total amount of trypsin bound was still the same 2 mol/mol $\alpha_2\text{M}$ but now only 0.6 mol was bound covalently by the same criterion [18]. Those results can be rationalized by proposing that on trypsin-induced activation the thiol esters of $\alpha_2\text{M}$ are cleaved to produce a highly reactive, short-lived intermediate, which will react with available nucleophiles, e.g., proteinase, methylamine, putrescine and probably water, leading to covalent incorporation of the respective nucleophile on the γ -carbonyl group of the reactive Glx-residue. This short-lived $\alpha_2\text{M}$ -intermediate is apparently the functional equivalent of the nascent C3b, as shown [23] to incorporate not only methylamine but also phenylhydrazine, glucosamine and glycerol. It may also be equivalent with the activated α' -chain of C4b [14] which binds IgG.

To see if proteins other than active proteinases can be incorporated into 'nascent' $\alpha_2\text{M}$, the experiments

shown in fig. 3 (TLCK-trypsin) and fig. 4 (insulin) were done. When present during proteinase-induced (trypsin) activation of $\alpha_2\text{M}$ 0.45 mol TLCK-trypsin/mol $\alpha_2\text{M}$ was incorporated (0.26 mol covalently by the gel-filtration criterion) for 2.14 mol active trypsin/mol $\alpha_2\text{M}$ (fig. 3). In the insulin case (fig. 4) up to 0.32 mol insulin/mol $\alpha_2\text{M}$ was incorporated (0.11 mol covalently) for 1.61 mol active trypsin/mol $\alpha_2\text{M}$. In the absence of active trypsin no incorporation of either protein was observed. Furthermore, when added 2 min after the active trypsin, only 0.07 mol TLCK-trypsin/mol $\alpha_2\text{M}$ was bound. Thus, TLCK-trypsin and insulin, both proteins lacking proteinase activity, can be incorporated into $\alpha_2\text{M}$, but only by its proteinase-activated 'nascent' form.

Earlier results, e.g. [24], indicating that $\alpha_2\text{M}$ could bind insulin can now be explained as having been due to ongoing partial activation to 'nascent' $\alpha_2\text{M}$ by active proteinases that must have been present because serum, not plasma, was used as a source of $\alpha_2\text{M}$.

Considering these results it becomes important to define the extent of proteolytic activation and thiol-




Fig. 3. Binding of TLCK- ^{125}I -trypsin to $\alpha_2\text{M}$ at different concentrations of active trypsin. Each $500\ \mu\text{l}$ sample of $\alpha_2\text{M}$ containing a 1.77-fold molar excess of TLCK- ^{125}I -trypsin was incubated with active trypsin for 2 min. Trypsin action was stopped by adding $100\ \mu\text{l}$ PTI ($1.54\ \text{mM}$). All samples were then subjected to gel chromatography in buffer A (○) on a column of Sephacryl S-300 ($1 \times 94\ \text{cm}$; $4.0\ \text{ml/h}$; $1.0\ \text{ml}$ fractions). The material from each sample, eluting in the position of $\alpha_2\text{M}$ (see fig. 1 of [18]) was pooled, precipitated with trichloroacetic acid (10%, w/v), collected, washed with ether, redissolved in $1.0\ \text{ml}$ buffer B ($0.5\ \text{M}$ Tris-HCl, $6\ \text{M}$ guanidine-HCl, pH 8.0), reduced ($20\ \mu\text{l}$ $0.5\ \text{M}$ DTT, $1\ \text{h}$) alkylated ($50\ \mu\text{l}$ $0.5\ \text{M}$ $\text{ICH}_2\text{CONH}_2$, $10\ \text{min}$) then rechromatographed in buffer B on Sephacryl S-300 ($1 \times 93\ \text{cm}$; $4.0\ \text{ml/h}$; $1.3\ \text{ml}$ fractions). (●) Represents TLCK- ^{125}I -trypsin remaining bound to $\alpha_2\text{M}$ fragments (eluting in tubes 23–33; see fig. 2 of [18]), under these denaturing conditions.




Fig.4. Binding of 125 I-labelled insulin to α_2 M at different concentrations of insulin. Samples (500 μ l) of α_2 M containing different amounts of 125 I-labelled insulin and unlabelled insulin were incubated with active trypsin at a 1.61-fold molar excess over α_2 M for 2 min. Following addition of PTI the samples were gel chromatographed in buffer A. A single experiment performed with a reduced, alkylated sample in buffer B showed that 0.11 mol insulin A-chain/mol α_2 M was covalently attached to α_2 M for 2.3 mol insulin added/mol α_2 M. The conditions for gel chromatography were as in fig.3.

ester cleavage in α_2 M preparations used in biological experiments, particularly studies of cellular uptake mechanisms.

These results further stress the functional relationship between α_2 M and C3 recognized in [1–3,5,6]. In particular it is striking that both proteins following proteolytic activation interact with their respective cell surface receptors, resulting in endocytosis of α_2 M–proteinase complexes [25–27] or opsonisation of complexes between C3b and cells [28–30].

Acknowledgements

We appreciate the technical assistance of Lene Kristensen, Mette Frandsen, Gitte Poulsen and Bente Christensen. Out-dated human plasma was obtained from The Blood Bank, Aarhus University Hospital through the courtesy of F. Kissmeyer-Nielsen, J. Jørgensen and S. Steenbjerg. This work was supported by The National Heart, Lung and Blood Institute, NIH (Bethesda MD) grant HL-16238.

References

- [1] Swenson, R. P. and Howard, J. B. (1979) *Proc. Natl. Acad. Sci. USA* 76, 4313–4316.

- [2] Sottrup-Jensen, L., Petersen, T. E. and Magnusson, S. (1980) *FEBS Lett.* 121, 275–279.
- [3] Sottrup-Jensen, L., Hansen, H. F., Mortensen, S. B., Petersen, T. E. and Magnusson, S. (1981) *FEBS Lett.* 123, 145–148.
- [4] Janatova, J., Lorenz, P. E., Schechter, A. N., Prahl, J. W. and Tack, B. F. (1980) *Biochemistry* 19, 4471–4478.
- [5] Pangburn, M. K. and Müller-Eberhard, H. J. (1980) *J. Exp. Med.* 152, 1103–1114.
- [6] Tack, B. F., Harrison, R. A., Janatova, J., Thomas, M. L. and Prahl, J. W. (1980) *Proc. Natl. Acad. Sci. USA* 77, 5764–5768.
- [7] Howard, J. B. (1980) *J. Biol. Chem.* 255, 7082–7084.
- [8] Barrett, A. J., Brown, M. A. and Sayers, C. A. (1979) *Biochem. J.* 181, 401–418.
- [9] Harpel, P. C. and Rosenberg, R. D. (1976) *Progr. Thromb.* 3, 145–189.
- [10] Pochon, F., Amand, B., Lavalette, D. and Bieth, J. (1978) *J. Biol. Chem.* 253, 7496–7499.
- [11] Salvesen, G. S. and Barrett, A. J. (1980) *Biochem. J.* 187, 695–701.
- [12] Law, S. K. and Levine, R. P. (1977) *Proc. Natl. Acad. Sci. USA* 74, 2701–2705.
- [13] Law, S. K., Fearon, D. T. and Levine, R. P. (1979) *J. Immunol.* 122, 759–765.
- [14] Campbell, R. D., Dodds, A. W. and Porter, R. R. (1980) *Biochem. J.* 189, 67–80.
- [15] Müller-Eberhard, H. J., Dalmasso, A. P. and Calcott, M. A. (1966) *J. Exp. Med.* 123, 33–54.
- [16] Robinson, N. C., Tye, R. W., Neurath, H. and Walsh, K. A. (1971) *Biochemistry* 10, 2743–2747.
- [17] Shaw, E. (1967) *Methods Enzymol.* 11, 677–686.
- [18] Sottrup-Jensen, L., Petersen, T. E. and Magnusson, S. (1981) *FEBS Lett.* 128, 127–132.
- [19] Linde, S., Hansen, B., Sonne, O., Holst, J. J. and Gliemann, J. (1981) *Diabetes* 30, 1–8.
- [20] Dunn, J. T. and Spiro, R. G. (1967) *J. Biol. Chem.* 242, 5549–5555.
- [21] Jones, J. M., Creeth, J. M. and Kekwick, R. A. (1972) *Biochem. J.* 127, 187–197.
- [22] Keil, B. (1971) in: *The Enzymes* (Boyer, P. ed) vol. 3, pp. 250–275, Academic Press, New York.
- [23] Sim, R. B., Twose, T. M., Paterson, D. S. and Sim, E. (1981) *Biochem. J.* 193, 115–127.
- [24] Adham, N. F., Wilding, P., Mehl, J. and Haverback, B. J. (1968) *J. Lab. Clin. Med.* 71, 271–282.
- [25] Debanne, M. T., Bell, R. and Dolovich, J. (1975) *Biochim. Biophys. Acta* 411, 295–354.
- [26] Van Leuven, F., Cassiman, J.-J. and Van den Berghe, H. (1979) *J. Biol. Chem.* 254, 5155–5160.
- [27] Kaplan, J. and Nielsen, M. L. (1979) *J. Biol. Chem.* 254, 7329–7335.
- [28] Huber, H., Polley, M. J., Linscott, W. D., Fudenberg, H. H. and Müller-Eberhard, H. J. (1968) *Science* 162, 1281–1283.
- [29] Gigli, I. and Nelson, R. A., jr (1968) *Exp. Cell. Res.* 51, 45–67.
- [30] Johnston, R. B., jr, Klemperer, M. R., Alper, C. A. and Rosen, F. S. (1969) *J. Exp. Med.* 129, 1275–1290.